Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for inflammatory and immune-mediated dermatological conditions. The company operates within the biotechnology and specialty pharmaceuticals industries, with an emphasis on dermatology. VYNE’s business model centers on advancing proprietary drug candidates through clinical development and, if approved, commercialization either independently or through strategic partnerships.
The company’s primary value drivers are its clinical-stage dermatology programs, particularly assets targeting chronic inflammatory skin diseases with significant unmet medical need. VYNE has positioned itself around novel mechanisms of action and topical or localized delivery approaches designed to improve efficacy and safety profiles compared to existing systemic therapies. The company traces its origins to 2018 under the name Menlo Therapeutics, later rebranding to VYNE Therapeutics following strategic shifts in its pipeline and corporate direction.
Business Operations
VYNE Therapeutics conducts its operations as a single reporting segment focused on pharmaceutical research and development. The company does not currently generate product revenue and relies on capital from equity financings and collaborations to fund operations. Its activities include preclinical research, clinical trial execution, regulatory strategy, and intellectual property management related to its dermatology-focused pipeline.
Operations are primarily based in the United States, with clinical trials conducted through a network of contract research organizations and clinical sites. The company controls proprietary drug candidates and related intellectual property rather than manufacturing or commercial infrastructure. VYNE does not report material revenue-generating subsidiaries and operates with a lean internal structure supported by external service providers.
Strategic Position & Investments
VYNE’s strategic direction is centered on advancing late preclinical and clinical dermatology assets while maintaining financial discipline through portfolio prioritization. The company has historically restructured its pipeline to focus resources on programs with clearer regulatory pathways and differentiated clinical profiles. Strategic decisions have included discontinuation of certain development programs and workforce reductions to extend cash runway.
The company’s key assets include repibresib gel (VYN201), a topical pan-bromodomain inhibitor in clinical development for non-melanoma inflammatory skin conditions, and VYN202, an oral BD2-selective BET inhibitor targeting immune-mediated diseases. VYNE does not currently report material equity investments or ownership stakes in other operating companies, and no significant acquisitions have been disclosed in recent public filings.
Geographic Footprint
VYNE Therapeutics is headquartered in the United States, with its principal executive offices located in Connecticut. The company’s operational footprint is primarily domestic, reflecting its focus on U.S.-based clinical development, regulatory engagement, and corporate management.
International exposure is limited and mainly tied to clinical research activities, including the use of investigative sites outside the U.S. when appropriate. VYNE does not maintain significant foreign offices or manufacturing facilities, and its global presence is best characterized as research-oriented rather than commercial.
Leadership & Governance
VYNE Therapeutics is led by an executive team with experience in biotechnology development, regulatory strategy, and capital markets. The leadership’s strategic vision emphasizes disciplined capital allocation, focus on core dermatology programs, and value creation through clinical milestones rather than broad pipeline expansion.
Key executives include:
- David Domzalski – President and Chief Executive Officer
- Keith A. Katkin – Chief Financial Officer
- Mark L. DeLong – Chief Medical Officer
- Pamela L. Schoppe – Chief Legal Officer and Corporate Secretary
The company is governed by a board of directors composed of individuals with backgrounds in biopharmaceutical leadership, finance, and corporate governance, consistent with publicly listed U.S. biotechnology companies.